title: Antenatal administration of vitamin K1: relationship to vitamin K-dependent coagulation factors and incidence rate of periventricular-intraventricular hemorrhage in preterm infants; Egyptian randomized controlled trial.
abstract: OBJECTIVE
  To determine the effect of maternal antenatal administration of vitamin K1 on activity level of vitamin K-dependent coagulation factors and on the occurrence of periventricular-intraventricular hemorrhage (PIVH).
  
  
  METHODS
  This study was conducted on 90 infants who were classified into; Group A: 30 preterm whose mothers received antenatal vitamin K1, Group B: 30 preterm whose mothers did not receive antenatal vitamin K1, and Group C: 30 healthy full term newborns as a control group. All newborns were subjected to measurement of the activity level of vitamin K-dependent coagulation factors (FII, FVII, FIX and FX). Cranial ultrasound was done on the 1st, 3rd and 7th days of life.
  
  
  RESULTS
  Group B showed significantly lower activity level of FII and FX with higher incidence of PIVH compared with group A. Neonates who developed PIVH by the 7th day in both group A and B had significantly lower activity level of vitamin K-dependent coagulation factors.
  
  
  CONCLUSIONS
  when antenatal vitamin K1 was given to pregnant women at imminent risk of preterm labor, their preterm neonates were able to achieve a clotting status approaching that of full term neonates and are less liable to develop PIVH.
authors.affiliation: Department of Pediatrics .
authors.forename: Mona M
authors.initials: MM
authors.lastname: El-Ganzoury
authors.forename: Rania A
authors.initials: RA
authors.lastname: El-Farrash
authors.forename: Abeer A
authors.initials: AA
authors.lastname: Saad
authors.forename: Mohamed S
authors.initials: MS
authors.lastname: Ali
authors.forename: Amany R
authors.initials: AR
authors.lastname: El-Bhbiti
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Selem
mesh_terms: D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000032:analysis / Q000187:drug effects*; D002543:Cerebral Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology*; D036861:Delivery, Obstetric / Q000379:methods / Q000706:statistics & numerical data; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005312:Fetal Blood / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000453:epidemiology*; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D010837:Vitamin K 1